Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.


Acar A. , Gerceker T., Ertam S., Ceylan C. , Ozturk G., Unal I.

Cutaneous and ocular toxicology, vol.39, pp.249-253, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39
  • Publication Date: 2020
  • Doi Number: 10.1080/15569527.2020.1787432
  • Title of Journal : Cutaneous and ocular toxicology
  • Page Numbers: pp.249-253
  • Keywords: Chronic spontaneous urticaria, omalizumab, adverse effect, relapse, remission, EFFICACY

Abstract

Purpose Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema that appears spontaneously due to known or unknown causes and lasts for at least 6 weeks. Omalizumab, an anti-IgE antibody that binds circulating free IgE, has recently emerged as a promising treatment for CSU, a condition which impairs patients' quality of life. We aimed to contribute real life data by reporting our experience with omalizumab in the treatment of intractable CSU. Methods Of 140 patients treated with omalizumab in our clinic between September 2013 and January 2018, 86 CSU patients with available current data were retrospectively evaluated in terms of sex, age, urticaria duration, urticaria activity score over 7 days (UAS7) before and after omalizumab, relapses and time to relapse, length of remission after omalizumab cessation, adverse events, and comorbidities. Results The mean age of the patients was 45.5 +/- 14.3 years and 73.3% were women. Mean duration of urticaria before initiation of omalizumab therapy was 54.5 +/- 67 months. All patients had used antihistamines before starting omalizumab treatment. The mean number of omalizumab doses was 11.9 +/- 9.3. The mean duration of omalizumab treatment was 13.3 +/- 10.4 months. Mean UAS7 score was 38.9 +/- 4.1 before the start of omalizumab treatment, and 7.9 +/- 10.5 after treatment. Treatment was discontinued in 10 patients (11.6%) due to nonresponse or loss of effect. Four patients (4.65%) experienced adverse events. Treatment was discontinued in 1 patient (1.16%) due to side effects. Of the 55 patients whose treatment was discontinued after their symptoms resolved, 31 (56.3%) relapsed after omalizumab cessation. Twenty-four patients (43.6%) did not relapse after omalizumab cessation. Conclusions Our results show that omalizumab was an effective treatment for intractable CSU and did not cause any serious adverse effects other than asthenia, vertigo, and injection site reaction in four patients. These findings are relevant because they reflect real-life data.